Drug Trial Radar · NCT06887192
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 15, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- MapLight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Conditions
- Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MADrug
ML-007C-MA dosed as 105/1.5 mg BID, or 210/3 mg BID
PlaceboDrug
Placebo Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) scoreTime frame: Baseline and End of Treatment (7 weeks)
Locations
69 sites in 15 countries. Site status is shown where the registry gives one.
Clinical Site
Phoenix, Arizona · Recruiting
Clinical Site
Scottsdale, Arizona · Recruiting
Clinical Site
Tucson, Arizona · Recruiting
Clinical Site
Anaheim, California · Recruiting
Clinical Site
Long Beach, California · Recruiting
Clinical Site
Murrieta, California · Recruiting
Clinical Site
Orange, California · Recruiting
Clinical Site
Redlands, California · Recruiting
Clinical Site
San Diego, California · Recruiting
Clinical Site
Denver, Colorado · Recruiting
Clinical Site
Boca Raton, Florida · Recruiting
Clinical Site
Deerfield Beach, Florida · Recruiting
Clinical Site
Doral, Florida · Recruiting
Clinical Site
Homestead, Florida · Recruiting
Clinical Site
Miami, Florida · Recruiting
Clinical Site
Miami, Florida · Recruiting
Clinical Site
Miami, Florida · Recruiting
Clinical Site
Miami, Florida · Recruiting
Clinical Site
Miami Gardens, Florida · Recruiting
Clinical Site
Miami Gardens, Florida · Recruiting
Clinical Site
Naples, Florida · Recruiting
Clinical Site
Orlando, Florida · Recruiting
Clinical Site
Tampa, Florida · Recruiting
Clinical Site
West Palm Beach, Florida · Recruiting
Clinical Site
Augusta, Georgia · Recruiting
Clinical Site
Snellville, Georgia · Recruiting
Clinical Site
Alexandria, Louisiana · Recruiting
Clinical Site
Las Vegas, Nevada · Recruiting
Clinical Site
West Long Branch, New Jersey · Recruiting
Clinical Site
New York, New York · Recruiting
Clinical Site
Dayton, Ohio · Recruiting
Clinical Site
Independence, Ohio · Recruiting
Clinical Site
Tigard, Oregon · Recruiting
Clinical Site
Port Royal, South Carolina · Recruiting
Clinical Site
Austin, Texas · Recruiting
Clinical Site
McKinney, Texas · Recruiting
Clinical Site
Sugarland, Texas · Recruiting
Clinical Site
Bellevue, Washington · Recruiting
Clinical Site
Córdoba, Argentina · Recruiting
Clinical Site
La Plata, Buenos Aires, Argentina · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.